LIXTE Biotechnology Holdings (NASDAQ: LIXT) spent 2025 expanding its presence across multiple segments of oncology innovation, focusing on its clinical-stage pipeline built around LB-100, a first-in-class inhibitor of protein phosphatase 2A (PP2A). Rather than replacing established cancer therapies, LB-100 is designed to enhance their effectiveness. By inhibiting PP2A, the compound stimulates cell-cycle progression and interferes with DNA repair in cancer cells, potentially making tumors more responsive to chemotherapy and immunotherapy.
LB-100 is currently being evaluated in multiple clinical programs targeting solid tumors with significant unmet medical need, including ovarian clear cell carcinoma, metastatic colon cancer and advanced soft tissue sarcoma. These proof-of-concept trials aim to demonstrate that LB-100 can improve outcomes for patients with these difficult-to-treat cancers.
The company's approach is based on extensive published preclinical data, which can be found at www.lixte.com. LIXTE’s lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. The company’s comprehensive patent portfolio covers this new approach.
For more details on the company's progress and the potential of LB-100, the full article is available at https://ibn.fm/iCydh. Investors should consider the forward-looking statements and risks outlined in the company’s filings with the SEC.
